Bevacizumab Maintenance Therapy in Metastatic Colorectal Cancer
Posted: Wednesday, April 11, 2018
Bevacizumab maintenance therapy during chemotherapy-free intervals seemed to have no effect in patients with metastatic colorectal cancer who underwent induction chemotherapy, according to the phase III PRODIGE 9, led by Thomas Aparicio, MD, PhD, of Saint Louis Hospital, Paris. No significant differences were found in tumor control duration, progression-free survival, or overall survival between treatment and observation groups. These results were published in the Journal of Clinical Oncology.
Researchers randomly assigned 491 patients 1:1 to receive bevacizumab maintenance or no maintenance therapy during chemotherapy-free intervals after induction chemotherapy. Both groups received 12 cycles of fluorouracil, leucovorin, and irinotecan plus bevacizumab. The induction regimen was repeated for eight cycles after disease progression, followed by a subsequent chemotherapy-free period. About half of study patients had at least one reinduction.
The median tumor control duration was 15 months for both groups. The median progression-free survival was 9.2 months with bevacizumab maintenance and 8.9 months with observation; median overall survival was 21.7 months vs. 22.0 months, respectively.
The authors concluded, “Additional research is needed to better define subgroups of patients who should receive maintenance chemotherapy after induction treatment or could undergo a true chemotherapy-free interval.”